Wei Liu – InmunoES

Pharmacovigilance analysis of infliximab in inflammatory bowel disease: novel safety signals and sex-specific adverse event profiles from the FAERS database (2004–2024)

24 de March de 2026 by Wei Liu

IntroductionInflammatory bowel disease (IBD) is a chronic immune-mediated gastrointestinal disease, and its global incidence is on the rise, which seriously affects the quality of life of patients. Infliximab is the key therapeutic drug for IBD, and a …

Correction: Association of body mass index changes with short-term mortality risks in ICU patients with sepsis across different admission BMI states: analysis of the MIMIC-IV database

23 de February de 2026 by Wei Liu

Association of body mass index changes with short-term mortality risks in ICU patients with sepsis across different admission BMI states: analysis of the MIMIC-IV database

24 de October de 2025 by Wei Liu

BackgroundStatic body mass index (BMI) is a known predictor of mortality in sepsis; however, the prognostic value of dynamic BMI trajectories across various admission BMI states remains unclear. This study aimed to quantify the dose–response relationsh…

Global research trends and hotspots for leukocyte cell-derived chemotaxin-2 from the past to 2023: a combined bibliometric review

31 de May de 2024 by Wei Liu

Leukocyte cell-derived chemotaxin-2 (LECT2) is an important cytokine synthesized by liver. Significant research interest is stimulated by its crucial involvement in inflammatory response, immune regulation, disease occurrence and development. However, …

Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity

3 de May de 2024 by Wei Liu

IntroductionCM313 is currently under clinical investigation for treatments of multiple myeloma, systemic lupus erythematosus, and immune thrombocytopenia. We aimed to report the preclinical profile of the novel therapeutic anti-CD38 monoclonal antibody…